GGrantIndex
← Leaderboards

Brian B Haab

Z Biotech, Llc

$9,258,497
Attributed
$17,576,966
Total exposure
13
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.1M · FY200525
$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$17,576,966 · 13

By mechanism

U01$11,216,487 · 3
R21$2,072,687 · 4
R44$1,646,945 · 1
R33$894,444 · 1
R43$878,543 · 2
R41$685,860 · 1

Top collaborators

Most similar at Z Biotech, Llc

Same institution · by research overlap

Others in their field

Top investigators on “Sampling

Research focus

SamplingPolysaccharidesMalignant Neoplasm Of PancreasMalignant NeoplasmsDetectionBiological MarkersSuccessLectinStructureBaseAntibodiesPerformanceGlycosylationPancreasProteinsResearch StudyVariantLeadAreaTechnologyMeasurementResearch PersonnelMolecularLaboratories

Grant awards (41)

Development of a GBP-based glycosylation analysis system$306,710
R43 · FY2025 · GM
Subpopulations of Pancreatic Cancer Cells Defined by Glycan Markers$620,756
U01 · FY2023 · CA · contact PI
Bioinformatic Tools for Interpretation of Glycan Array Data$544,916
R44 · FY2023 · GM
Subpopulations of Pancreatic Cancer Cells Defined by Glycan Markers$643,951
U01 · FY2022 · CA · contact PI
Bioinformatic Tools for Interpretation of Glycan Array Data$544,916
R44 · FY2022 · GM
Subpopulations of Pancreatic Cancer Cells Defined by Glycan Markers$625,227
U01 · FY2021 · CA · contact PI
Bioinformatic Tools for Interpretation of Glycan Array Data$557,113
R44 · FY2021 · GM
Detection and prognosis of early-stage pancreatic cancer by interdependent plasma markers$374,611
U01 · FY2021 · CA · contact PI
Subpopulations of Pancreatic Cancer Cells Defined by Glycan Markers$671,698
U01 · FY2020 · CA · contact PI
Detection and prognosis of early-stage pancreatic cancer by interdependent plasma markers$548,627
U01 · FY2020 · CA · contact PI
Subpopulations of Pancreatic Cancer Cells Defined by Glycan Markers$617,734
U01 · FY2019 · CA · contact PI
Bioinformatic Tools for Interpretation of Glycan Array Data$571,833
R43 · FY2019 · GM
Detection and prognosis of early-stage pancreatic cancer by interdependent plasma markers$521,859
U01 · FY2019 · CA · contact PI
Glyco-typer: an antibody capture glycan imaging methodology$391,987
R21 · FY2019 · CA
Detection and prognosis of early-stage pancreatic cancer by interdependent plasma markers$553,441
U01 · FY2018 · CA · contact PI
Glyco-typer: an antibody capture glycan imaging methodology$339,424
R21 · FY2018 · CA
Detection and prognosis of early-stage pancreatic cancer by interdependent plasma markers$554,248
U01 · FY2017 · CA · contact PI
On-chip Glycan Analysis of Clinical Specimens$304,618
R21 · FY2017 · AI · contact PI
Detection and prognosis of early-stage pancreatic cancer by interdependent plasma markers$623,533
U01 · FY2016 · CA · contact PI
Targeted Glycomics and Affinity Reagents for Cancer Biomarker Development$440,750
U01 · FY2016 · CA · contact PI
On-chip Glycan Analysis of Clinical Specimens$326,443
R21 · FY2016 · AI · contact PI
Targeted Glycomics and Affinity Reagents for Cancer Biomarker Development$433,792
U01 · FY2015 · CA · contact PI
Comprehensive Glycoproteomic Tool Development for Cancer Biomarkers$342,930
R41 · FY2015 · GM
Detection of Pre-Invasive Pancreatic Cysts Using Protein and Glycan Biomarkers$101,267
U01 · FY2015 · CA · contact PI
Targeted Glycomics and Affinity Reagents for Cancer Biomarker Development$426,426
U01 · FY2014 · CA · contact PI
Detection of Pre-Invasive Pancreatic Cysts Using Protein and Glycan Biomarkers$389,914
U01 · FY2014 · CA · contact PI
Comprehensive Glycoproteomic Tool Development for Cancer Biomarkers$342,930
R41 · FY2014 · GM
Detection of Pre-Invasive Pancreatic Cysts Using Protein and Glycan Biomarkers$530,069
U01 · FY2013 · CA · contact PI
Targeted Glycomics and Affinity Reagents for Cancer Biomarker Development$425,890
U01 · FY2013 · CA · contact PI
Targeted Glycomics and Affinity Reagents for Cancer Biomarker Development$554,934
U01 · FY2012 · CA · contact PI
Detection of Pre-Invasive Pancreatic Cysts Using Protein and Glycan Biomarkers$224,231
U01 · FY2012 · CA · contact PI
Detection of Pre-Invasive Pancreatic Cysts Using Protein and Glycan Biomarkers$601,107
U01 · FY2011 · CA · contact PI
Detection of Pre-Invasive Pancreatic Cysts Using Protein and Glycan Biomarkers$732,422
U01 · FY2010 · CA · contact PI
Defining Secreted Glycan Alterations in Pancreatic Cancer$277,884
R33 · FY2010 · CA · contact PI
Induced Glycan Alterations in Sub-populations of Pancreatic Tumors$91,000
R03 · FY2010 · CA · contact PI
Defining Secreted Glycan Alterations in Pancreatic Cancer$282,400
R33 · FY2009 · CA · contact PI
Induced Glycan Alterations in Sub-populations of Pancreatic Tumors$91,000
R03 · FY2009 · CA · contact PI
Defining Secreted Glycan Alterations in Pancreatic Cancer$334,160
R33 · FY2008 · CA · contact PI
Defining Secreted Glycan Alterations in Pancreatic Cancer$325,417
R21 · FY2006 · CA · contact PI
Longitudinal Cancer-Specific Serum Protein Signatures$177,958
R21 · FY2006 · CA · contact PI
Longitudinal Cancer-Specific Serum Protein Signatures$206,840
R21 · FY2005 · CA